Given the present findings, both the serum and urine CCL2 levels are considered biomarkers of the proof of pharmacology for CKD, strengthening this QC/isoQC inhibition approach for managing CKD over other inhibitors of CCL2/CCR2 that lack such a biomarker. The gene discussed is CCL2; the disease is chronic kidney disease.